Introduction: Epstein-Barr virus (EBV)-associated gastric cancer (GC) represents a distinct molecular subtype of the disease, characterized by specific immunological and genetic features. Viral entry and persistence may be associated with modulation of the expression of genes related to cell adhesion, immune response, and intercellular communication. This study aimed to evaluate the expression profiles of the genes ITGA5, ITGB1, TGFB1, EPHA2, NRP1, and CR2 in EBV-positive and EBV-negative GC samples, in order to identify potential targets involved in tumor biology and viral infection. Objective: To evaluate the expression profiles of the genes ITGA5, ITGB1, TGFB1, EPHA2, NRP1, and CR2 in Epstein-Barr virus-positive and -negative gastric cancer samples, aiming to identify potential molecular targets involved in tumor biology and viral infection. Methods: Public transcriptomic data from the GSE51575 dataset, available in the Gene Expression Omnibus (GEO) database, were used. Differential expression analysis was conducted using the GEO2R tool, comparing EBV-positive and EBV-negative gastric cancer samples. The genes of interest were manually mapped in the results table based on their identifiers and full names. Results: Among the genes evaluated, ITGA5, ITGB1, TGFB1, EPHA2, and NRP1 showed detectable expression in the samples, with variations between the EBV-positive and EBV-negative groups. Although most genes did not reach statistical significance after correction for multiple testing, a trend toward overexpression of ITGA5 and EPHA2 was observed in EBV-positive samples, suggesting possible involvement in virus-cell interaction. The CR2 gene was not clearly detected in the dataset samples. Conclusion: Preliminary results indicate possible differences in the expression of genes involved in cell adhesion and signaling in EBV-associated gastric tumors. These findings support further investigations into the role of these genes in viral infection and tumor progression, as well as reinforce the usefulness of public databases for exploratory studies in oncovirology.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
